VANCOUVER, Nov. 7, 2013 /CNW/ - iCo Therapeutics Inc. (TSX-V: ICO),
today announced that Management will be presenting at the 5th Annual Ophthalmology Innovation Summit (OIS). A corporate presentation,
highlighting the Company's Phase 2 iDEAL Study for diabetic macular
edema (DME), will take place at 10:54 am EST, Thursday November 14th,
2013 at the Sheraton New Orleans.
"We're very happy to once again be invited to this prestigious event,"
said Andrew Rae, President & CEO of iCo. "Our phase 2 study in patients
with diabetic macular edema is ongoing with a recent endorsement of the
Data and Safety Monitoring Committee. We are now preparing to report on
our primary end point data in early 2014. This conference highlights a
number of private and public companies, including some firms who have
conducted high profile initial public offerings, and is a great
platform to be in front of the who's who in the ophthalmology space at
a very critical time for the company".
The OIS is a premier ophthalmology conference that seeks to unite
leaders in the development of ophthalmic products, drugs, and devices.
For more information please refer to: http://www.ophthalmologysummit.com/.
About iCo Therapeutics
iCo Therapeutics in-licenses and redefines existing drug candidates or
generics by employing reformulation and delivery technologies for new
or expanded use indications. The company has exclusive worldwide rights
to two drug candidates - iCo-007 for Diabetic Macular Edema (DME) and
iCo-008 for other sight-threatening diseases. iCo-007 is in Phase 2
clinical studies for DME. With Phase 2 clinical history, iCo-008 is
targeted for the treatment of keratoconjunctivitis and wet age-related
macular degeneration. In addition, iCo holds worldwide rights to an
oral drug delivery platform. The first platform candidate is the Oral
Amp B Delivery system, utilizing a known anti-fungal drug to treat
life-threatening infectious diseases. iCo trades on the TSX Venture
Exchange under the symbol "ICO". For more information, visit the
Company website at: www.icotherapeutics.com.
No regulatory authority has approved or disapproved the content of this
release. The TSX Venture Exchange does not accept responsibility for
the adequacy or accuracy of this release.
Forward Looking Statements
Certain statements included in this press release may be considered
forward-looking statements" within the meaning of the safe harbor
provisions of the U.S. Private Securities Litigation Reform Act of
1995. Forward-looking statements can be identified by words such as:
"anticipate," "intend," "plan," "goal," "seek," "believe," "project,"
"estimate," "expect," "strategy," "future," "likely," "may," "should,"
"will," and similar references to future periods. Such statements
involve known and unknown risks, uncertainties and other factors that
may cause actual results, performance or achievements to be materially
different from those implied by such statements, and therefore these
statements should not be read as guarantees of future performance or
results. All forward-looking statements are based on iCo's current
beliefs as well as assumptions made by and information currently
available to iCo and relate to, among other things, anticipated
financial performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which are based only on information currently available to
iCo and speak only as of the date of this press release. Due to risks
and uncertainties, including the risks and uncertainties identified by
iCo in its public securities filings and on its website, actual events
may differ materially from current expectations. iCo disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or
SOURCE: iCo Therapeutics Inc.
For further information:
Mr. John Meekison, CFO
604-602-9414 x 224
Michael Moore, Investor Relations